Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 113

    1.

    Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases.

    Twum-Danso NA.

    Filaria J. 2003 Oct 24;2 Suppl 1:S3.

    PMID:
    14975060
    [PubMed - as supplied by publisher]
    Free PMC Article
    3.

    Variation in incidence of serious adverse events after onchocerciasis treatment with ivermectin in areas of Cameroon co-endemic for loiasis.

    Twum-Danso NA, Meredith SE.

    Trop Med Int Health. 2003 Sep;8(9):820-31.

    PMID:
    12950668
    [PubMed - indexed for MEDLINE]
    Free Article
    4.

    Report of a Scientific Working Group on Serious Adverse Events following Mectizan(R) treatment of onchocerciasis in Loa loa endemic areas.

    Scientific Working Group on Serious Adverse Events in Loa Loa endemic areas.

    Filaria J. 2003 Oct 24;2 Suppl 1:S2.

    PMID:
    14975059
    [PubMed - as supplied by publisher]
    Free PMC Article
    5.

    Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection.

    Gardon J, Gardon-Wendel N, Demanga-Ngangue, Kamgno J, Chippaux JP, Boussinesq M.

    Lancet. 1997 Jul 5;350(9070):18-22.

    PMID:
    9217715
    [PubMed - indexed for MEDLINE]
    6.

    Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis.

    Boussinesq M, Gardon J, Gardon-Wendel N, Kamgno J, Ngoumou P, Chippaux JP.

    Am J Trop Med Hyg. 1998 Apr;58(4):461-9.

    PMID:
    9574793
    [PubMed - indexed for MEDLINE]
    Free Article
    7.

    Combined Utilisation of Rapid Assessment Procedures for Loiasis (RAPLOA) and Onchocerciasis (REA) in Rain forest Villages of Cameroon.

    Wanji S, Tendongfor N, Esum M, Yundze SS, Taylor MJ, Enyong P.

    Filaria J. 2005 Apr 7;4(1):2.

    PMID:
    15817124
    [PubMed - as supplied by publisher]
    Free PMC Article
    8.

    Mass treatment of onchocerciasis with ivermectin: should people with epilepsy and/or growth-retardation syndromes be excluded?

    Twum-Danso NA.

    Ann Trop Med Parasitol. 2004 Mar;98(2):99-114. Review.

    PMID:
    15035720
    [PubMed - indexed for MEDLINE]
    9.

    Structure of the microfilarial reservoir of Loa loa in the human host and its implications for monitoring the progr,ammes of Community-Directed Treatment with Ivermectin carried out in Africa.

    Pion DS, Gardon J, Kamgno J, Gardon-Wendel N, Chippaux JP, Boussinesq M.

    Parasitology. 2004 Nov;129(Pt 5):613-26.

    PMID:
    15552406
    [PubMed - indexed for MEDLINE]
    10.

    Programmatic and Communication Issues in Relation to Serious Adverse Events Following Ivermectin Treatment in areas Co-endemic for Onchocerciasis and Loiasis.

    Haselow NJ, Akame J, Evini C, Akongo S.

    Filaria J. 2003 Oct 24;2 Suppl 1:S10.

    PMID:
    14975067
    [PubMed - as supplied by publisher]
    Free PMC Article
    11.

    The Mectizan Donation Program (MDP).

    Thylefors B.

    Ann Trop Med Parasitol. 2008 Sep;102 Suppl 1:39-44.

    PMID:
    18718154
    [PubMed - indexed for MEDLINE]
    12.

    [Analysis of the prevention of post-ivermectin Loa loa encephalopathy by administration of initial low dose].

    Kamgno J, Gardon J, Boussinesq M.

    Med Trop (Mars). 2000;60(3):275-7. French.

    PMID:
    11258063
    [PubMed - indexed for MEDLINE]
    13.

    Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients.

    Mackenzie CD, Geary TG, Gerlach JA.

    Filaria J. 2003 Oct 24;2 Suppl 1:S5.

    PMID:
    14975062
    [PubMed - as supplied by publisher]
    Free PMC Article
    14.

    Analysis of the mdr-1 gene in patients co-infected with Onchocerca volvulus and Loa loa who experienced a post-ivermectin serious adverse event.

    Bourguinat C, Kamgno J, Boussinesq M, Mackenzie CD, Prichard RK, Geary TG.

    Am J Trop Med Hyg. 2010 Jul;83(1):28-32.

    PMID:
    20595473
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    15.

    Genetic heterogeneity in Loa loa parasites from southern Cameroon: A preliminary study.

    Higazi TB, Klion AD, Boussinesq M, Unnasch TR.

    Filaria J. 2004 Jun 29;3(1):4.

    PMID:
    15225348
    [PubMed - as supplied by publisher]
    Free PMC Article
    16.

    [Ivermectin].

    Boussinesq M.

    Med Trop (Mars). 2005;65(1):69-79. Review. French.

    PMID:
    15903082
    [PubMed - indexed for MEDLINE]
    17.

    Prevalences of Loa loa microfilaraemia throughout the area endemic for the infection.

    Boussinesq M, Gardon J.

    Ann Trop Med Parasitol. 1997 Sep;91(6):573-89. Review.

    PMID:
    9425360
    [PubMed - indexed for MEDLINE]
    18.

    Control of onchocerciasis.

    Boatin BA, Richards FO Jr.

    Adv Parasitol. 2006;61:349-94. Review.

    PMID:
    16735169
    [PubMed - indexed for MEDLINE]
    19.

    Loa loa microfilarial periodicity in ivermectin-treated patients: comparison between those developing and those free of serious adverse events.

    Kamgno J, Pion SD, Mackenzie CD, Thylefors B, Boussinesq M.

    Am J Trop Med Hyg. 2009 Dec;81(6):1056-61.

    PMID:
    19996437
    [PubMed - indexed for MEDLINE]
    Free Article
    20.

    Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon.

    Boussinesq M, Gardon J, Gardon-Wendel N, Chippaux JP.

    Filaria J. 2003 Oct 24;2 Suppl 1:S4.

    PMID:
    14975061
    [PubMed - as supplied by publisher]
    Free PMC Article

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk